Hemophilia Affects Sex Life, According to a Small-Sample Survey of Men with the Condition
Forty percent of men with hemophilia who responded to a survey said the condition can weigh on their sex life,…
Articles by Patricia Inácio, PhD
Phase 3 Trial to Assess Shire’s Adynovate for Better Bleed Protection
Shire has launched a Phase 3 clinical trial (NCT02585960) with Adynovate, a drug approved to help treat and control bleeding…
New Formula of Recombinant Factor VIII in Kids with Severe Hemophilia A Is Effective, Trial Shows
A new, modified version of recombinant factor VIII (rFVIII), called rVIII-SingleChain, showed great efficacy and safety in treating bleeding events…
Daily Infusion of Low-dose Factor VIII Found to Benefit Some Hemophilia A Patients
A daily infusion of low-dose factor VIII (FVIII) improves trough levels in patients with severe hemophilia A — compared to infusions…
Extending Coagulation Factor Activity Improves Joint Healing in Mice with Hemophilia
Damaged joints and bones in mice with hemophilia benefit from extended activity of coagulation factor IX, research shows. The study, “…
CRISPR/Cas9 Gene-Editing Strategy Successfully Used in Hemophilia B Mice
Researchers have successfully applied a potential gene therapy for hemophilia B based on the genome editing properties of the CRISPR/Cas9…
Hemophilia B Is Less Severe than Hemophilia A, Suggesting Therapeutic Differences
Recent evidence suggests that hemophilia B is clinically less severe than hemophilia A, highlighting the need to discuss further therapeutic options…
New Strategy Improves Protein Drugs by Looking into Past
Scientists have improved protein drugs using an approach based on “ancestral sequence reconstruction,” or ASR. The newly established strategy promises…
Hemophilia A Patients May Benefit from Specific Replacement Therapy
A recent clinical trial indicates that replacement therapy with plasma-derived factor VIII is associated with lower incidence for development of…